Featured Research

from universities, journals, and other organizations

Battle against prostate, bladder cancer: License deal signals major breakthrough

Date:
March 6, 2014
Source:
University of Surrey
Summary:
A new license announced will bring to market a new test that will help with the early detection of prostate and bladder cancers. Scientists have developed a more reliable way of detecting prostate and bladder cancers, by testing a small urine sample. The team focused on the EN2 protein produced by these types of cancers, and which is secreted into urine. Clinical trials in both Europe and the United States have found that the EN2 biomarker test is twice as effective as the 30-year-old PSA blood test currently used to detect prostate cancer.

A new license announced today between the University of Surrey and Randox, will bring to market a new test that will help with the early detection of prostate and bladder cancers.

Related Articles


Scientists at the University of Surrey have developed a more reliable way of detecting prostate and bladder cancers, by testing a small urine sample. The team focused on the EN2 protein produced by these types of cancers, and which is secreted into urine. Clinical trials in both Europe and the United States have found that the EN2 biomarker test is twice as effective as the 30-year-old PSA blood test currently used to detect prostate cancer.

The University of Surrey will supply key materials to Randox to manufacture and market products. It is hoped that a test could be made available in GP surgeries around the world, by 2015.

Hardev Pandha, Professor of Medical Oncology at the University of Surrey, said: "We are looking forward to working with Randox on this product. This new test could lead to faster detection that could save hundreds of lives, and also offers the potential for huge cost savings.

"Unlike in previous tests that require invasive procedures to produce a trigger, our studies show that the EN2 test immediately shows up and that levels of the protein correlate strongly with how far the disease has spread. This may then help a doctor assess whether the disease may be safely and actively monitored, or whether it has spread more widely and requires treatment."

Dr Peter FitzGerald, Randox Laboratories Founder and Managing Director, said: "With prostate and bladder cancers being among the top ten common causes of cancer death, accurate diagnosis is incredibly important to inform the type of treatment. We are therefore delighted to be working with the University of Surrey to develop and commercialise an EN2 biomarker. The concept of personalised medicine will shape the future of diagnostics and healthcare in general. Building relationships between academics, clinicians, industry and, of course, patients demonstrates how basic science discoveries made at the laboratory bench can be translated into clinical products that have real tangible impact for patients, the economy and society in general."


Story Source:

The above story is based on materials provided by University of Surrey. Note: Materials may be edited for content and length.


Cite This Page:

University of Surrey. "Battle against prostate, bladder cancer: License deal signals major breakthrough." ScienceDaily. ScienceDaily, 6 March 2014. <www.sciencedaily.com/releases/2014/03/140306093609.htm>.
University of Surrey. (2014, March 6). Battle against prostate, bladder cancer: License deal signals major breakthrough. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2014/03/140306093609.htm
University of Surrey. "Battle against prostate, bladder cancer: License deal signals major breakthrough." ScienceDaily. www.sciencedaily.com/releases/2014/03/140306093609.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins